This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Principia gets $50mm through Series B round; round closes at $65.9mm
20 Aug 2018
Principia BioPharma Inc. (small-molecule therapeutics for autoimmune diseases, inflammation, and oncology) raised $50mm through its Series B round. Sofinnova Ventures led (and takes a board seat) and was joined by all of Principia’s existing investors, including Morgenthaler Ventures, New Leaf Venture Partners, OrbiMed, SR One, Mission Bay capital, and others. Proceeds will fund advancement of the company’s preclinical pipeline, comprised of an oral BTK inhibitor for autoimmune disease and cancer, an oral selective FGFR inhibitor for solid tumors, and an IL-17 pathway inhibitor for a variety of autoimmune and inflammatory diseases.
Drug Discovery Tools
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?